RESEARCH ARTICLE

Genetic relationship between Hashimoto’s thyroiditis and papillary thyroid carcinoma with coexisting Hashimoto’s thyroiditis

Ohoud Subhi1*, Hans-Juergen Schulten1*, Nadia Bagatian1, Ro’a Al-Dayini1, Sajjad Karim1, Sherin Bakhashab2,3, Reem Alotibi1,2, Alaa Al-Ahmadi1,2, Manar Ata1, Aisha Elaimi3, Saad Al-Muhayawi1, Majid Mansouri4, Khalid Al-Ghamdi4, Osman Abdel Hamour5, Atawif Jamal6, Jaudah Al-Maghrabi6,7, Mohammed Hussain Al-Qahtani1

1 Center of Excellence in Genomic Medicine Research, Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia, 2 Department of Biochemistry, Faculty of Sciences, King Abdulaziz University, Jeddah, Saudi Arabia, 3 Center of Innovation in Personalized Medicine, Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia, 4 Department of Otolaryngology, Head and Neck Surgery, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia, 5 Department of Surgery, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia, 6 Department of Pathology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia, 7 Department of Pathology, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia

These authors contributed equally to this work.

hschulten@kau.edu.sa

Abstract

Hashimoto’s thyroiditis (HT) is present in the background of around 30% of papillary thyroid carcinomas (PTCs). The genetic predisposition effect of this autoimmune condition is not thoroughly understood. We analyzed the microarray expression profiles of 13 HT, eight PTCs with (w/) coexisting HT, six PTCs without (w/o) coexisting HT, six micro PTCs (mPTCs), and three normal thyroid (TN) samples. Based on a false discovery rate (FDR)-adjusted p-value ≤ 0.05 and a fold change (FC) > 2, four comparison groups were defined, which were HT vs. TN; PTC w/ HT vs. TN; PTC w/o HT vs. TN; and mPTC vs. TN. A Venn diagram displayed 15 different intersecting and non-intersecting differentially expressed gene (DEG) sets, of which a set of 71 DEGs, shared between the two comparison groups HT vs. TN ∩ PTC w/ HT vs. TN, harbored the relatively largest number of genes related to immune and inflammatory functions; oxidative stress and reactive oxygen species (ROS); DNA damage and DNA repair; cell cycle; and apoptosis. The majority of the 71 DEGs were upregulated and the most upregulated DEGs included a number of immunoglobulin kappa variable genes, and other immune-related genes, e.g., CD86 molecule (CD86), interleukin 2 receptor gamma (IL2RG), and interferon, alpha-inducible protein 6 (IFI6). Upregulated genes preferentially associated with other gene ontologies (GO) were, e.g., STAT1, MMP9, TOP2A, and BRCA2. Biofunctional analysis revealed pathways related to immunogenic functions. Further data analysis focused on the set of non-intersecting 358 DEGs derived from the comparison group of HT vs. TN, and on the set of 950 DEGs from the intersection of all four comparison groups. In conclusion, this study indicates that, besides immune/ inflammatory-related genes, also genes associated with oxidative stress, ROS, DNA
damage, DNA repair, cell cycle, and apoptosis are comparably more deregulated in a data set shared between HT and PTC w/ HT. These findings are compatible with the conception of a genetic sequence where chronic inflammatory response is accompanied by deregulation of genes and biofunctions associated with oncogenic transformation. The generated data set may serve as a source for identifying candidate genes and biomarkers that are practical for clinical application.

Introduction

Hashimoto’s thyroiditis (HT), also known as chronic lymphocytic thyroiditis, is induced by an autoimmune response where immune cells produce autoantibodies that target thyroid antigens, in first instance thyroid peroxidase (TPO) and thyroglobulin (TG) leading to atrophy and transformation of thyroid cells [1, 2]. This autoimmune reaction is caused by infiltrating autoreactive T lymphocytes and other components of the immune defense system that constitute an inflammatory infiltrate, which under chronic conditions leads to thyroiditis and hypothyroidism [2, 3]. Risk factors for HT include environmental factors, such as exposure to ionizing radiation, carcinogenic chemicals, iodine deficiency, and infections, as well as non-environmental risk factors, such as genetic susceptibility, that can be linked in certain cases with a history of inherited autoimmune diseases [4, 5]. Genome-wide association studies (GWAS) have identified a number of genetic susceptibility loci that are associated with autoimmunity, especially with development of thyroid autoantibodies [6, 7]. A systematic review on studies, carried out in their majority on Caucasian populations, reported that incidence of hypothyroidism, which is commonly associated with HT, is 350/100,000/year in women and 80/100,000/year in men [8]. Although controversial discussed, several studies including a meta-analysis on fine-needle aspiration (FNA) and thyroidectomy studies reported HT as a risk factor for papillary thyroid carcinoma (PTC) development, and this observation was mainly based on the proportionally higher incidence of PTC with (w/) HT compared to PTC without (w/o) HT [9, 10].

Thyroid carcinoma (TC) is the most common malignant endocrine cancer with a worldwide increasing incidence and especially PTC as the most common type of thyroid carcinoma contributes to this prevalence [11]. Micro PTCs (mPTCs) are ≤ 10 mm in size and regarded as a low risk and indolent subtype of PTC [12-14]. The mortality rates in TC are approximately between 0.20 and 0.60/100,000/year in women and 0.20 and 0.40/100,000/year in men [11]. The female prevalence observed in most of the thyroid lesions is also dominant in PTC w/ HT where cancer incidence is approximately five times higher in females than in males [15]. A meta-analysis on 71 observational studies reported that PTCs w/ HT are more likely to be multifocal but in general have favorable clinicopathological features including less extrathyroid extension, lymph node and distant metastases, and recurrence than PTCs w/o HT [16].

Reactive oxygen species (ROS), which are DNA damaging agents, are a physiological component of thyroid cell function and have elevated expression in HT. For example, a study on public-accessible RNA sequencing (RNA-seq) and microarray data provided genomic evidence that up-regulated genes related to ROS metabolism and apoptosis were significantly more prevalent in PTC w/ HT compared to PTC w/o HT [17]. This led to the notion that higher ROS levels in HT may contribute to PTC development. An immunohistochemistry (IHC) study on PTC-associated tumor markers suggested that in HT, under prolonged exposure to chronic inflammation, a fraction of follicular epithelia show PTC-like nuclear aberrations that might lead to oncogenic transformation [18]. Collaborating with this, a number of
studies identified molecular events common to both HT and TC. For instance, loss of heterozygosity (LOH) in the DNA damage repair gene 8-oxoguanine DNA glycosylase (OGG1) has been frequently found in HT and PTCs, but rarely in benign goiter [19]. An IHC study detected, in comparison to normal thyroid tissue, elevated expression of pAKT and the two isoforms AKT1, AKT2 in HT and in well-differentiated TC w/ or w/o HT [20]. In contrast, tumor suppressor PTEN showed positive expression in normal thyroid tissue and HT but only heterogeneous/absent expression in TC w/ HT. Another IHC study detected positive TP63 expression in HT and PTC, which led to the suggestion that both entities share a pathobiological relationship [21]. Furthermore, ret proto-oncogene (RET)/PTC rearrangements have been detected in a FISH and real-time PCR study at low frequencies in follicular cells of HT, which led to the assumption that these fusions may contribute to early stages of PTC development [22]. In contrast, BRAF mutations that are almost mutually exclusive to RET/PTC rearrangements, are not present in HT w/o coexisting PTC and are comparably more prevalent in PTC w/o HT [23].

The primary aim of the present study was to identify genes and biofunctions, which are shared between HT and PTC w/ HT. Findings should help to better understand the molecular etiopathogenesis between HT and PTC w/ HT and support further assessment of candidate genes for clinical application.

Material and methods
Tumor samples
For microarray expression analysis, 33 thyroid tissue specimens derived from partial or entire thyroidectomies were preserved in RNAlater (Qiagen Inc., Hilden, Germany) and selected for this study according to the histopathology reports. Age of patients ranged between 14 and 67 years with a mean age of 38.7 years, SD = 14.1 (S1 Table). Five of the six micro PTCs (mPTCs) coexisted with HT. The study was approved by the Biomedical Ethics Unit, Faculty of Medicine, King Abdulaziz University, (approval number: 358–10), and the Institutional Review Board of King Faisal Specialist Hospital and Research Center (approval number: IRB2010-07). Written informed consent from the donors or the next of kin was obtained for the use of samples in research. Microarray CEL files from three normal thyroid (TN) samples were downloaded from a website of the microarray vendor (Thermo Fisher Scientific, Waltham, MA) and served as control.

Sample processing
Total RNA was isolated from the samples using the RNeasy Mini-Kit according to the manufacturer’s protocol (Qiagen Inc.). RNA concentration was determined using the NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific). RNA integrity was assessed in three cases by gel electrophoretic RNA separation and in 30 cases by using the 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). The RNA integrity number (RIN) in these 30 samples ranged between 5.9 and 9.3 (mean, 7.66) and included only RNA in the acceptable quality range between nearly intact and slightly degraded RNA (chosen RIN cutoff value for clinical tumor samples, 5.0). The processed RNA samples were hybridized to HuGene 1.0 ST microarrays according to established protocols [24]. The labeled and washed microarrays were scanned on a GeneChip Scanner 3000 7G and CEL files were generated by the GeneChip Command Console Software AGCC (Thermo Fisher Scientific).

BRAF mutational status
Sequence analysis of BRAF exon 15 on PCR products, by using either a genomic DNA template or a cDNA template, was essentially reported earlier [24, 25].
Raw data analysis

The CEL files were imported into Partek Genomic Suite version 6.6 (Partek Inc., Chesterfield, MO) where expression data were normalized using the robust multi-array average (RMA) method in the default settings. A principal component analysis (PCA) was then conducted on the categorized samples and subsequently, lists of significantly differentially expressed genes (DEGs) (false discovery rate (FDR)-adjusted p-value < 0.05 and fold change (FC) > 2) were computed for the four comparison groups HT vs. TN; PTC w/ HT vs. TN; PTC w/o HT vs. TN; and mPTC vs. TN. Statistical assessment of a comparison group HT w/ PTC vs. HT w/o PTC generated no DEGs (FDR-adjusted p-value < 0.05 and FC > 2). From DEGs, represented by multiple probe sets, the set with the highest FC was selected for further processing. To generate intersecting and non-intersecting DEG sets from different comparison groups, a web-based Venn diagram tool was employed (http://bioinformatics.psb.ugent.be/webtools/Venn/) (S2 Table). Where applicable, the Ensemble genome browser and HUGO Gene Nomenclature Committee (HGNC) multi symbol checker were utilized to annotate gene IDs according to the approved symbols [26, 27]. An expression dendrogram was generated using the online web tool Heatmapper and employing average linkage clustering and Spearman's rank correlation for distance measurement on the gene set [28]. The generated microarray data set has been deposited at the NCBI's Gene Expression Omnibus (GEO) under accession number GSE138198 and includes renormalized sample files from submission GSE54958.

Gene ontology (GO)

GO annotations of the generated data set were compiled from different resources (S3 Table). Genes related to immune and inflammatory functions were retrieved from the online GO resource AmiGo2 v2.5.12 (search strings: immun, interleukin, histocompat, inflamm, cytokine, chemokine, interferon, lymphocyte) [29]. Cell cycle genes were retrieved from the The Molecular Signatures Database (msigdb) v7.0 [30] and a vendor resource (https://www.qiagen.com/nl/resources/resourcedetail?id=0ee18e97-d445-4fd7-9aa4-0ef4bece124f&lang=en). Apoptosis genes were derived from AmiGo2 (search string: apoptosis) and a vendor resource (https://www.qiagen.com/ch/resources/resourcedetail?id=e5252c51-7513-44a0-b66d-927c53e0eb2&lang=en). DNA damage and DNA repair genes were compiled from a publication resource [31], a database of DNA damage response-related proteins (DDRprot) [32], and a vendor resource (https://www.qiagen.com/sa/resources/resourcedetail?id=909a9567-91e0-43d9-96c7-a700182c3a&lang=en). ROS-related genes were retrieved from AmiGo2 (search strings: reactive oxygen species, oxidative stress) and a vendor resource (https://www.qiagen.com/us/products/discovery-and-translational-research/pcr-qpcr/qpcr-assays-and-instruments/mrna-incrna-qpcr-assays-panels/rt2-profiler-pcr-arrays/?catno=PAHS-065Z&geneglobe). A comprehensive list of genes mutated in differentiated thyroid cancer was acquired from the cBioPortal for Cancer Genomics [33]. Gene IDs of ncRNAs were downloaded from a HGNC webpage [27]. All files from the vendor and HGNC were accessed in August 2019.

Pathway and network analysis

Biological significance of DEGs was further interpreted using the Ingenuity Pathway Analysis software and its pathway Knowledge Base (IPA; build version 485516M; Qiagen Inc.). Analysis settings included direct and indirect molecular relationships. Fisher's exact test p-values indicated significant relationships between analyzed data set molecules and frameworks prebuilt or generated de novo by the software application. The Molecule Activity Predictor was employed to predict expression effects of a molecule on other pathway/network molecules as noted in the prediction legends of the respective figures. The overlap percentage in canonical
pathways indicates the relative number between uploaded and predefined pathway molecules. Network analysis was performed to explore significance of fit, expressed as a score, between uploaded data set molecules and networks related to specific diseases and functions. The upstream analysis module was employed to assess, by utilizing z-scores, in how far differences in target gene expression are affected by upstream regulators.

**Results**

To narrow down the genetic relationship between HT and PTC w/ HT, in reference to PTC w/o HT, mPTC, and TN, we analyzed the molecular expression profiles of a case series consisting of 13 HTs, eight PTCs w/ HT, six PTCs w/o HT, six mPTCs, and three TN samples. Demographic and clinicopathological data of the case series are listed in S1 Table. All tumors, except one, were stage I cases and a V600E BRAF mutation was revealed in eight cases. Similarity of expression profiles of the different groups of cases is presented in a PCA 3D scatter plot demonstrating that expression profiles of the different thyroid disease groups partially overlap whereas TN samples clearly cluster separately (Fig 1). Four comparison groups of DEGs were generated, i.e., HT vs. TN; PTC w/ HT vs. TN; PTC w/o HT vs. TN; and mPTC vs. TN. A Venn diagram displays the number of annotated DEGs, which are either unique for a comparison group or are shared between two or more comparison groups (Fig 2) (S2 Table). In our study, we focused in first instance on the 71 DEGs, which were shared between the two comparison groups HT vs. TN \ PTC w/ HT vs. TN. In further instance, we focused on the non-shared 358 DEGs derived from the comparison group HT vs. TN and on the 950 DEGs, which are shared between the four comparison groups, i.e., HT vs. TN \ PTC w/ HT vs. TN \ PTC w/o HT vs. TN \ mPTC vs. TN. Top canonical pathways and networks that are most significantly related to the 71, 358, and 950 DEG sets are to varying degrees enriched in immunogenic functions (Table 1).

For all 15 DEG sets, a GO classification in various categories was performed to generate an approximate overview of the functional implications of the sets. The 71 DEGs from the intersection of HT vs. TN \ PTC w/ HT vs. TN harbored the relatively highest number of DEGs related to immune and inflammatory functions; oxidative stress and ROS; DNA damage and DNA repair; cell cycle; and apoptosis (Fig 3).

**Analysis of the 71 DEG set from the intersection of HT vs. TN \ PTC w/ HT vs. TN**

Sixty of the 71 DEGs were comparably upregulated whereas only 11 DEGs were downregulated. The most significantly upregulated genes included a number of immunoglobulin kappa variable genes, i.e., IGKV3D-11, IGKV1-13, IGKV1D-16, IGKV1D-33, IGKV1D-42, and IGKV1D-43. Further overexpressed immune-related genes comprised MHC class II gene HLA-DQB1, immune checkpoint gene CD 86 molecule (CD86), interleukin 2 receptor, gamma (IL2RG), and interferon, alpha-inducible protein 6 (IFI6). Overexpressed genes, preferentially related to other GOs, included, e.g., ras-related C3 botulinum toxin substrate 2 (Rac family small GTPase 2 (RAC2), ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4 (ST8SIA4), tryptophanyl-tRNA synthetase 4 (STT8SIA4), tryptophanyl-tRNA synthetase 1 (WARS1, alias WARS), STAT1, membrane spanning 4-domains A6A (MS4A6A), BCL2 antagonist/killer 1 (BAK1), polo-like kinase 4 (PLK4), cytochrome b-245 beta chain (CYBB), and phosphoprotein membrane anchor with glycosphingolipid microdomains 1 (PAG1), MMP9, TOP2A, BRCA2, forkhead box M1 (FOXM1), and H2B clustered histone 14 (H2BC14). Among the most comparably underexpressed genes were EYA transcriptional coactivator and phosphatase 4 (EYA4), adhesion G protein-coupled receptor G7 (ADGRG7), acetyl-CoA dehydrogenase, long chain (ACADL), and erythrocyte
membrane protein band 4.1 like 5 (EPB41L5). A merged network and an upstream analysis, which are most significantly related to the 71 DEGs, are displayed in Figs 4 and 5, respectively, and a hierarchical cluster analysis of the 71 DEG set is illustrated in S1 Fig.

Analysis of the non-intersecting 358 DEG set derived from the comparison group HT vs. TN

In the 358 DEG set, approximately 80% of the genes were upregulated. In contrast to the 71 DEG set, the most upregulated genes included also several immunoglobulin heavy variable genes, i.e., IGHV3-35, IGHV3-43, IGHV3-52, IGHV3-73, IGHV3-74, IGHV4-59, IGHV5-78, IGHV3OR15-7, IGHV3OR16-7, IGHV3OR16-8, and IGHV1OR15-1. Other overexpressed immune-related genes comprised a number of chemokines, i.e., CXCL13, CCL19, CCL4L2, CCL4, and furthermore, the CD3 chain genes CD3G, CD3E, and CD3D, the non-receptor type 22 (lymphoid) (PTPN22), and
the immune checkpoint genes CD28 and programmed cell death 1 ligand 2 (PDCD1LG2). Overexpressed genes related to other GOs included, e.g., BCL2-related protein A1 (BCL2A1), marker of proliferation Ki-67 (MKI67), and the tumor suppressor Ras association domain family member 6 (RASSF6). Among underexpressed genes were thrombospondin 4 (THBS4), ephrin-A1 (EFNA1), insulin-like growth factor 1 receptor (IGF1R), adhesion G protein-coupled receptor F5 (ADGRF5), and the membrane-bound MMP14. A merged network, which is most significantly related to the 358 DEG set, is displayed in Fig 6.

Analysis of the 950 DEG set from the intersection of all four comparison groups
In the 950 DEG set, the number up- and downregulated genes was nearly the same. Among genes with highest overexpression were several small nucleolar RNAs, e.g., SNORA71D,
SNORD45A, SNORA16A, SNORD29, SNORD13P3, SNORD13, and SNORA22. Other overexpressed genes comprised a number of chemokines, including the chemokine (C-X-C motif) ligands CXCL10 and CXCL16. Among important oncogenes were poly (ADP-ribose) polymerase family, member 3 (PARP3), TGFB1, TP53, and EPH receptor B2 (EPHB2). Underexpressed genes included, e.g., superoxide dismutase 1, soluble (SOD1), superoxide dismutase 2, mitochondrial (SOD2), RAD21 homolog (S. pombe) (RAD21), BRCA1, and vascular endothelial growth factor D (VEGFD). A merged network, which is most significantly related to the 950 DEG set, is displayed in Fig 7.
Discussion

This is one of the first microarray expression studies that established gene expression profiles simultaneously in HT, PTCs w/ HT, PTCs w/o HT, mPTCs, and TN samples. By applying a categorization scheme, we were able to generate a comprehensive overview of DEGs shared or non-shared between different types of thyroid lesions with a focus on HT and PTC w/ HT. In the intersection of PTC w/ HT vs. TN ⊂ PTC w/o HT vs. TN we found for instance a strong downregulation of TPO, which is in line with its well-characterized low expression levels in PTC [34].

Although the link between ROS, inflammation and cancer has been extensively discussed, the underlying molecular genetics are not fully explored yet [35]. An expression analysis study on a publicly deposited RNA-seq data set focused on detection of ROS-related genes in PTCs w/ HT vs. PTCs w/o HT and identified 33 genes that were upregulated in PTCs w/ HT compared to nine in PTCs w/o HT [17]. Furthermore, the study found a considerable overlap of the identified upregulated ROS genes with a publicly deposited microarray expression data set. The immune-related expression pattern of genes in PTC was investigated in a number of studies. An protein expression study detected endogenous IgG\(\gamma\) and IgG\(\kappa\) expression in the majority of PTC and colocalization of IgG\(\gamma\) with complement proteins led to the suggestion that immune complexes are formed that may promote PTC cells from escaping the immune response against tumor antigens [36]. The hypothesis that the immunogenic link between HT and PTC may stimulate their synchronous appearance was also discussed in detail [37].
Fig 4. The top three merged networks that are based on the 71 DEGs from the intersection of HT vs. TN ∩ PTC w/ HT vs. TN. Upregulated molecules from the DEG set include ALOX5AP, APOBEC3F, BAK1, BRCA2, CCNB2, CD86, CYBB, EPST11, FANCD2, FCGR2B, FOXM1, HIST1H2BM, HIST2H3A, HLA-DQB1, IFI30, IFI6, IFIH1, IL2RG, KNTC1, LYN, MMP9, MOXD1, PAG1, PLK4, PSME2, PTPI6, RAC2, RIPK2, SAMD9, SLCA7A, ST8SIA4, STAT1, TOP2A, TRANK1, TRAPP1, and WARS. Downregulated molecules from the DEG set include ACADL, ADGRG7, EPB41L5, EYA4, PSMC6, RAB18, RBP4, and RETREG1. Integrative molecules from the IPA Knowledge Base comprise 26s Proteasome, ADAM22, Akt, APP, BCR (complex), caspase, Ck2, COL14A1, Creb, CUL3, CXL14, CXXR1, Cyclin E, DENND2D, ERK1/2, F2RL3, Fc gamma receptor, GRB10, Histone h3, Histone h4, HLA-DR, Hsp70, Hsp90, HSPA1A/HSPA1B, IFN alpha/beta, IFN Beta, Ifn gamma, IFN type 1, Iga, Igm, IL12 (complex), IL-2R, Immunglobulin, Interferon alpha, JAK, LMNA, Mek, MTHFD2, NADPH oxidase, ORMDL3, PADI4, PAK6, PDGF BB, phosphatase, PTK, Rb, RGS18, RNA polymerase II, SCO2, SSTR2, STAT5a/b, TIGD1, TMEM102, Tnf receptor, TNK1, TP53, TRAPP1, Ubiquitin, VAV, WDR5, and YWHAE.

https://doi.org/10.1371/journal.pone.0234566.g004

Upregulated genes of the 71 DEG set from the intersection of HT vs. TN ∩ PTC w/ HT vs. TN

The top upregulated genes in the 71 DEG set included a number of immunoglobulin kappa variables. Expression of light chains has been demonstrated in the vast majority of HT in a flow cytometry study where most cases showed a κ/λ light chain ratio in the range of non-lymphomatous polyclonality [38]. In a preclinical model system, tumor growth could be reduced by inhibiting free light chain-mediated mast cell activation [39]. The MHC class II gene HLA-DQB1 has been reported in a microarray expression assay to be differentially expressed between PTC and follicular variant of PTC (FVPTC) [40]. The immunoglobulin superfamily member CD86 is expressed on antigen-presenting cells (APCs) and involved in B-T cell
interaction and activation. Flow cytometry analysis in blood of patients with early onset Graves' disease and HT detected increased CD86 expression in thyroid-reactive B cells [41]. IL2RG is a critical signaling component of a number of interleukin receptors and has been described in a systems biology approach as a factor involved in T cell differentiation signaling during progression of PTC [42]. IFI6 is implicated in apoptosis regulation and exhibits a role in hepatitis C virus infection [43]. The polysialyltransferase ST8SIA4 has been identified in a multiplex meta-analysis of RNA expression datasets as one of the top deregulated genes associated with various immune dysfunctions [44]. STAT1 is implicated in signaling of IFN and a number of interleukins and therefore represents a critical factor of the normal immune response. In addition, STAT1 participates to the morphology and function of the thyroid [45]. An IHC study in HT indicated that tyrosine-phosphorylated STAT1 staining was associated with thyrocytes to oncocytes transformation as well as with a fraction of infiltrating lymphocytes and germinal macrophages [46]. Of notice, STAT1 constitutes a molecular target for anti-inflammatory treatment [47].

The putative tumor suppressor gene PAG1 encodes a transmembrane adaptor protein that binds to the tyrosine kinase Csk and participates in the negative control of T cell receptor (TCR) signaling [48]. The cytoplasmic enzyme WARS1 catalyzes the ligation of tryptophan to its cognate tRNA during the translation process and beyond this,
exerts diverse biological functions in innate immunity, angiogenesis, and IFNG signaling [49]. A microarray mRNA expression profiling study in several major blood cell subtypes derived from normal individuals identified a comparable overexpression of $MS4A6A$ in monocytes/platelets [50]. The function of $MS4A6A$ in autoimmune-related thyroid lesions remains to be elucidated.

The small GTPase Rac2 is involved in various aspects of host defense including integrin and immunoreceptor signaling, polarization to M2 macrophages and generation of ROS [51–53]. Rac2 knockout mice demonstrated a pronounced impairment in tumor growth, angiogenesis, and metastasis [52]. The membrane-bound CYBB is part of the catalytic core of an NADPH oxidase multi-protein complex that produces a phagocytic respiratory burst by generating superoxide in response to pathogens and various other stimuli [53]. The proapoptotic BAK1 protein is a BCL2 family member and an inducer of the intrinsic apoptotic pathway. All
three genes, encoding for RAC2, CYBB, and BAK1, were reported to be deregulated among ROS-related genes in an RNA-seq data set analysis between PTC w/ HT and PTC w/o HT [17]. Overexpression of the zinc-dependent metalloproteinase MMP9 has been previously associated with invasion of follicular ML-1 thyroid cancer cells [54]. Furthermore, in vitro assays demonstrated that MMP9 expression is necessary for the serine/threonine kinase ROCK1 to promote PTC cell invasion [55]. TOP2A is a critical factor for sister chromosome segregation and is expressed at highest levels in G2 and M cell cycle phases. The enzyme induces double-stranded DNA breaks, which activate autoimmune regulator (Aire)-associated proteins leading to increased and efficient gene transcription [56].
protein kinase PLK4 is involved in initiating centriole assembly. Its reversible inhibition may represent a prospective anticancer therapy [57]. Upregulation of BRCA2 is likely a DNA repair response mechanism to elevated DNA damage under chronic ROS exposure. The transcription factor FOXM1 is involved in many crucial biological processes and specifically related to cell cycle progression and cancer evolution [58, 59]. FOXM1 overexpression was detected by IHC in 28.4% of PTCs [60]. Further in vitro and in vivo study found that the FOXM1 inhibitor thiostrepton inhibited PTC cell line xenograft tumor growth and this was accompanied by downregulation of FOXM1, MMP9, and MMP2. H2BC14, alias HIST1H2BM, has been identified as one of several molecules that participate in progression through the cell cycle and that are regulated by the p53-p21-DREAM-E2F/CHR pathway [59].

**Downregulated genes of the 71 DEG set from the intersection of HT vs. TN \(\cap\) PTC w/ HT vs. TN**

Downregulation of EYA4 expression in cells of epithelial origin is consisting with its tumor suppressor function in these entities [61]. ADGRG7, alias GPR128, is a receptor of the adhesion GPCR family, whose functional relevance in thyroid lesions is virtually unknown; however, promoter studies indicated that ESRα and SP1 play a critical role in positively regulating expression of the receptor [62, 63]. ACADL is a peroxisomal enzyme and is part of a family of enzymes known to be regulated by thyroid hormones [64]. Epb41l5 is implicated in the post-transcriptional regulation of cadherin Cdh1 and cell adhesion molecule Itgb1 during epithelial-mesenchymal transition (EMT) and this transition is inhibited by Epb41l5 silencing [65].

**Non-intersecting 358 DEG set derived from the comparison group HT vs. TN**

The predominant overexpression of IGHV genes, especially IGHV3, that are used for generating autoantibody against TPO is consistent with a review reporting that expression of these genes is associated with HT [66]. Of notice, all IGHV3 genes in our data compilation were included in the 358 DEG set. Similarly, the CD3 components, which were contained in our data compilation, i.e., CD3G, CD3E, and CD3D, were highly overexpressed in the 358 DEG set. In T cells, these molecules generate activation signals when associated in a complex with the TCR. Therapies with CD3 autoantibodies in combination with other therapeutics are envisaged to improve safety and optimize efficacy for treatment of various autoimmune diseases [67]. PDCD1LG2 is expressed from APCs whereas CD28 is expressed from T cells and both immune checkpoint molecules are implicated in inhibitory and stimulatory T cell signaling, respectively [68]. Also of notice, a pronounced number of critical immunomodulators, which were described in an immunogenomic analysis of major TCGA cancer data sets and included PDCD1LG2, BTN3A2, GZMA, BTLA, CD28, ICOS, and IDO1, were contained in the 358 DEG set [69]. The intracellular phosphatase PTPN22 is implicated in immune cell signaling and known as a predisposing gene for autoimmune diseases [70]. A non-synonymous polymorphism in this gene is associated with enhanced susceptibility to a variety of autoimmune diseases [71]. PTPN22 may constitute a target for cancer immunotherapy [70].

**The 950 DEG set from the intersection of all four comparison groups**

CXCL10 is known as one of the key immunomodulators in cancer and its high expression upon combined INFγ and TNFA stimulation has been demonstrated in primary thyrocyte cell cultures [72]. PARP3 is a member of the poly(ADP-ribose) polymerases and is implicated in biological relevant functions including DNA-repair mechanisms and cell cycle regulation [73]. In in vitro experiments, PARP3 expression assisted in TGFB-induced and ROS-supported EMT [74]. PARP3 may gain relevance as a therapeutic target in cancer treatment [75].
An IHC study found a significant association of TP53 positivity in TC with thyroiditis [76]. Increased apoptosis was detected in a case series of HT and thyroid tumors, and it was noted that elevated TP53 and/or CDKN1A protein expression is an indication for possible DNA damage and enhanced apoptosis in HT [77]. Both SOD1 and SOD2, which catalyze the dismutation of superoxide radicals into less reactive hydrogen peroxide and oxygen, were significantly higher expressed in the thyroid lesions compared to TN. A microarray expression analysis of the Oncomine database demonstrated that SOD2 is higher expressed in PTCs and pronounced higher expressed in anaplastic thyroid carcinoma in comparison to normal thyroid tissue [78]. RAD21 is a component of the cohesion core complex that is a critical regulator of sister chromatid cohesion and chromosome segregation. Loss of RAD21 impairs genomic loop domains [79]. Deregulation of RAD21 has been observed in a number of cancers [80]. Different mechanisms of BRCA1 downregulation have been described [81]. Knockdown of BRAC1 in breast cancer cells resulted in increased phospho-Akt and enhanced susceptibility of the cells to PI3K/AKT pathway inhibitors [82]. The secreted prolymphangiogenic factor VEGFD is implicated in tumor growth; however, decreased serum levels of VEGFD were measured in patients with metastatic differentiated thyroid carcinoma [83].

Conclusion

Taken together, this microarray expression study provides a comprehensive overview on DEGs and biofunctions in the thyroid lesions under investigation with a primary focus on those that are shared between HT and PTC w/ HT. Our findings are in line with the conception that in HT a lymphocytic infiltrate is associated with chronic exposure to ROS that promotes DNA damage resulting in oncogenic transformation of thyroid cells. The comprehensive lists of DEGs and biofunctions may serve as a source to assess therapeutic targets and biomarkers, especially in HT and PTC w/ HT.

Supporting information

S1 Fig. Hierarchical cluster analysis on the expression values of the 71 DEG set from the intersection of HT vs. TN ∩ PTC w/ HT vs. TN. Expression values were plotted for all 36 samples analyzed in this study, i.e., 13 HT, eight PTCs w/ HT, six PTCs w/o HT, six mPTCs, and three TN samples. Red and green colors display higher and lower expression values of samples, respectively.

(TIF)

S1 Table. Clinicopathological and demographic data of the case series.

(XLSX)

S2 Table. P-values and fold change of the 15 intersecting and non-intersecting DEG sets derived from the four comparison groups HT vs. TN; PTC w/ HT vs. TN; PTC w/o HT vs. TN; and mPTC vs. TN.

(XLSX)

S3 Table. Genes listed in different gene ontologies.

(XLSX)

Acknowledgments

We thank Manal Shabaat, Lobna Siraj Mira, Alaa Ghazi Almasri, Sabrin Bukhari, and Shireen Hussain for excellent technical assistance. We would also like to thank Dr. Mohammed M. Badri, Faculty of Medicine, King Abdulaziz University, for his contribution to the study.
Author Contributions

Conceptualization: Ohoud Subhi, Hans-Juergen Schulten.

Data curation: Hans-Juergen Schulten, Sajjad Karim, Saad Al-Muhayawi, Majid Mansouri, Khalid Al-Ghamdi, Osman Abdel Hamour, Awatif Jamal, Jaudah Al-Maghrabi.

Formal analysis: Ohoud Subhi, Hans-Juergen Schulten, Sajjad Karim.

Funding acquisition: Hans-Juergen Schulten.

Investigation: Ohoud Subhi, Nadia Bagatian, Roa’a Al-Dayini, Reem Alotibi, Alaa Al-Ahmadi, Manar Ata, Khalid Al-Ghamdi, Awatif Jamal, Jaudah Al-Maghrabi.

Methodology: Ohoud Subhi, Hans-Juergen Schulten, Nadia Bagatian, Roa’a Al-Dayini, Reem Alotibi, Alaa Al-Ahmadi, Manar Ata, Aisha Elaimi.

Project administration: Mohammed Hussain Al-Qahtani.

Resources: Sherin Bakhashab, Aisha Elaimi, Saad Al-Muhayawi, Majid Mansouri, Khalid Al-Ghamdi, Osman Abdel Hamour, Awatif Jamal, Jaudah Al-Maghrabi, Mohammed Hussain Al-Qahtani.

Software: Sajjad Karim.

Supervision: Hans-Juergen Schulten, Sajjad Karim, Aisha Elaimi, Saad Al-Muhayawi, Majid Mansouri, Osman Abdel Hamour, Jaudah Al-Maghrabi, Mohammed Hussain Al-Qahtani.

Validation: Hans-Juergen Schulten.

Writing – original draft: Ohoud Subhi, Hans-Juergen Schulten, Sherin Bakhashab.

Writing – review & editing: Hans-Juergen Schulten, Jaudah Al-Maghrabi, Mohammed Hussain Al-Qahtani.

References

1. Caturegli P, De Remigis A, Rose NR. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmunity reviews. 2014; 13(4–5):391–7. Epub 01/13. https://doi.org/10.1016/j.autrev.2014.01.007 PMID: 24434360.

2. Rydzewska M, Jaromin M, Pasierowska IE, Stozek K, Bosowski A. Role of the T and B lymphocytes in pathogenesis of autoimmune thyroid diseases. Thyroid research. 2018; 11(2). Epub 2018/02/17. https://doi.org/10.1186/s13044-018-0046-9 PMID: 29449887; PubMed Central PMCID: PMC5812228.

3. Zaletel K, Gabersček S. Hashimoto’s Thyroiditis: From Genes to the Disease. Current genomics. 2011; 12(8):576–88. Epub 2012/06/02. https://doi.org/10.2174/138920211798120763 PMID: 22654557; PubMed Central PMCID: PMC3271310.

4. Dong YH, Fu DG. Autoimmune thyroid disease: mechanism, genetics and current knowledge. European review for medical and pharmacological sciences. 2014; 18(23):3611–8. Epub 2014/12/24. PMID: 25535130.

5. Balazs C. [The role of hereditary and environmental factors in autoimmune thyroid diseases]. Orvosi hetilap. 2012; 153(26):1013–22. Epub 2012/06/28. https://doi.org/10.1556/OH.2012.29370 PMID: 22735372.

6. Hwangbo Y, Park YJ. Genome-Wide Association Studies of Autoimmune Thyroid Diseases, Thyroid Function, and Thyroid Cancer. Endocrinology and metabolism (Seoul, Korea). 2018; 33(2):175–84. Epub 2018/06/28. https://doi.org/10.3803/EnM.2018.33.2.175 PMID: 29947174; PubMed Central PMCID: PMC6021314.

7. Brcic L, Baric A, Gracan S, Torlak V, Brekalo M, Skrabric V, et al. Genome-wide association analysis suggests novel loci underlying thyroid antibodies in Hashimoto’s thyroiditis. Scientific reports. 2019; 9 (1):5360. Epub 2019/03/31. https://doi.org/10.1038/s41598-019-41850-6 PMID: 30926877; PubMed Central PMCID: PMC6440971.
8. McGrogan A, Seaman HE, Wright JW, de Vries CS. The incidence of autoimmune thyroid disease: a systematic review of the literature. Clinical endocrinology. 2008; 69(5):687–96. https://doi.org/10.1111/j.1365-2265.2008.03338.x PMID: 18673466.

9. Lai X, Xia Y, Zhang B, Li J, Jiang Y. A meta-analysis of Hashimoto’s thyroiditis and papillary thyroid carcinoma risk. Oncotarget. 2017; 8(37):52414–24. Epub 2017/10/06. https://doi.org/10.18632/oncotarget.18620 PMID: 28977955; PubMed Central PMCID: PMC5617515.

10. Ferrari SM, Fallahi P, Elia G, Ragusa F, Ruffilli I, Paparo SR, et al. Thyroid autoimmune disorders and cancer. Seminars in cancer biology. 2019. Epub 2019/06/04. https://doi.org/10.1016/j.semcancer.2019.05.019 PMID: 31158464.

11. La Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F, et al. Thyroid cancer mortality and incidence: a global overview. International journal of cancer. 2015; 136(9):2187–95. Epub 2014/10/07. https://doi.org/10.1002/ijc.29251 PMID: 25284703.

12. Fatourehci V. Managing the increasing diagnosis of papillary micro-cancer of thyroid. Expert review of endocrinology & metabolism. 2015; 10(5):467–9. Epub 2015/09/01. https://doi.org/10.1586/17446651.2015.1063996 PMID: 30298758.

13. Hahn LD, Kunder CA, Chen MM, Orloff LA, Desser TS. Indolent thyroid cancer: knowns and unknowns. Cancers of the head & neck. 2017; 2:1. Epub 2017/01/11. https://doi.org/10.1186/s41199-016-0021-x PMID: 31093348; PubMed Central PMCID: PMC6460732.

14. Ito Y, Miyauuchi A, Oda H. Low-risk papillary microcarcinoma of the thyroid: A review of active surveillance trials. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2018; 44(3):307–15. Epub 2017/03/28. https://doi.org/10.1016/j.ejso.2017.03.004 PMID: 28343733.

15. Resende de Paiva C, Gronhøj C, Feldt-Rasmussen U, von Buchwald C. Association between Hashimoto Thyroiditis and Thyroid Cancer in 64,628 Patients. Frontiers in Oncology. 2017; 7:53. Epub 2017/04/27. https://doi.org/10.3389/fonc.2017.00053 PMID: 28443243; PubMed Central PMCID: PMC5385456.

16. Moon S, Chung HS, Yu JM, Yoo HJ, Park JH, Kim DS, et al. Associations between Hashimoto Thyroiditis and Clinical Outcomes of Papillary Thyroid Cancer: A Meta-Analysis of Observational Studies. Endocrinology and metabolism (Seoul, Korea). 2018; 33(4):473–84. Epub 2018/12/05. https://doi.org/10.3830/EnM.2018.33.4.473 PMID: 30513562; PubMed Central PMCID: PMC6279904.

17. Yi JW, Park JY, Sung JY, Kwak SH, Yu J, Chang JH, et al. Genomic evidence of reactive oxygen species elevation in papillary thyroid carcinoma with Hashimoto thyroiditis. Endocrine journal. 2015; 62(10):857–77. Epub 2015/07/28. https://doi.org/10.1507/endocrj.EJ15-0234 PMID: 26211532.

18. Ma H, Yan J, Zhang C, Qin S, Qin L, Liu L, et al. Expression of papillary thyroid carcinoma-associated molecular markers and their significance in follicular epithelial dysplasia with papillary thyroid carcinoma-like nuclear alterations in Hashimoto’s thyroiditis. International journal of clinical and experimental pathology. 2014; 7(11):7999–8007. Epub 2015/01/01. PMID: 25550843; PubMed Central PMCID: PMC4270599.

19. Royer MC, Zhang H, Fan CY, Kokoska MS. Genetic alterations in papillary thyroid carcinoma and hashimoto thyroiditis: An analysis of hOGG1 loss of heterozygosity. Archives of otolaryngology—head & neck surgery. 2010; 136(9):2240–2. https://doi.org/10.1001/archoto.2010.20 PMID: 20331640.

20. Larson SD, Jackson LN, Riall TS, Uchida T, Thomas RP, Qiu S, et al. Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. Journal of the American College of Surgeons. 2007; 204(5):764–75. Epub 2007/02/23. https://doi.org/10.1016/j.jcscr.2007.05.019 PMID: 17481480.

21. Unger P, Ewart M, Wang BY, Gan L, Kohtz DS, Burstein DE. Expression of p63 in papillary thyroid carcinoma and in Hashimoto’s thyroiditis: a pathobiologic link? Human pathology. 2003; 34(8):764–9. Epub 2003/09/25. https://doi.org/10.1016/s0046-8177(03)00239-9 PMID: 14506636.

22. Rhoden KJ, Unger K, Salvatore G, Yilmaz Y, Vovk V, Chiappetta G, et al. RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto’s thyroiditis share low-level recombination events with a subset of papillary carcinoma. The Journal of clinical endocrinology and metabolism. 2006; 91(6):2414–23. Epub 2006/04/06. https://doi.org/10.1210/jc.2006-0240 PMID: 16595592.

23. Kim KH, Suh KS, Kang DW, Kang DY. Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto’s thyroiditis. Pathology international. 2005; 55(9):540–5. Epub 2005/09/07. https://doi.org/10.1111/j.1440-1827.2005.01866.x PMID: 16143028.

24. Schulten HJ, Alotibi R, Al-Ahmadi A, Ata M, Karim S, Huwai E, et al. Effect of BRAF mutational status on expression profiles in conventional papillary thyroid carcinoma. BMC genomics. 2015; 16 Suppl 1: S6. Epub 2015/04/30. https://doi.org/10.1186/1471-2164-16-s1-s6 PMID: 25922907; PubMed Central PMCID: PMC4315163.
25. Schulten HJ, Salama S, Al-Mansouri Z, Alothbi R, Al-Ghamdi K, Al-Hamour OA, et al. BRAF mutations in thyroid tumors from an ethnically diverse group. Hereditary cancer in clinical practice. 2012; 10(1):10. Epub 2012/08/29. https://doi.org/10.1186/1897-4287-10-10 PMID: 22925390; PubMed Central PMCID: PMC3434056.

26. Hunt SE, McLaren W, Gil L, Thorannen A, Schulenberg H, Sheppard D, et al. Ensembl variation resources. Database: the journal of biological databases and curation. 2018; 2018. Epub 2018/12/24. https://doi.org/10.1093/database/bay119 PMID: 30576484; PubMed Central PMCID: PMC6310513.

27. Braschi B, Denny P, Gray K, Jones T, Seal R, Tweedie S, et al. Genenames.org: the HGNC and VNC resources in 2019. Nucleic acids research. 2019; 47(D1):D786–d92. Epub 2018/10/12. https://doi.org/10.1093/nar/gky930 PMID: 30304474; PubMed Central PMCID: PMC6324057.

28. Babicki S, Arndt D, Marcu A, Liang Y, Grant JR, Maciejewski A, et al. Heatmapper: web-enabled heat mapping for all. Nucleic acids research. 2016; 44(W1):W147–53. Epub 2016/05/18. https://doi.org/10.1093/nar/gkw419 PMID: 27190236; PubMed Central PMCID: PMC4987948.

29. The Gene Ontology Resource: 20 years and still GOing strong. Nucleic acids research. 2019; 47(D1):D755–63. Epub 2018/10/01. https://doi.org/10.1093/nar/gky930 PMID: 30395331; PubMed Central PMCID: PMC6323945.

30. Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell systems. 2015; 1(6):417–25. Epub 2016/01/16. https://doi.org/10.1016/j.cels.2015.12.004 PMID: 26771021; PubMed Central PMCID: PMC4707969.

31. Chae YK, Anker JF, Carneiro BA, Chandra S, Kaplan J, Kalyan A, et al. Genomic landscape of DNA repair genes in cancer. Oncotarget. 2016; 7(17):23312–21. Epub 2016/03/24. https://doi.org/10.18632/oncotarget.8196 PMID: 27004405; PubMed Central PMCID: PMC5029628.

32. Andres-Leon E, Cases I, Arcas A, Rojas AM. DDrprot: a database of DNA damage response-related proteins. Database: the journal of biological databases and curation. 2016; 2016. Epub 2016/09/01. https://doi.org/10.1093/database/baw123 PMID: 27577567; PubMed Central PMCID: PMC5004197.

33. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science signaling. 2013; 6(269):p1. Epub 2013/04/04. https://doi.org/10.1126/scisignal.2004088 PMID: 23552010; PubMed Central PMCID: PMC4160307.

34. Tanaka T, Umeaki K, Yamamoto I, Sugiyama S, Noguchi S, Ohtaki S. Immunohistochemical loss of thyroid peroxidase in papillary thyroid carcinoma: strong suppression of peroxidase gene expression. The Journal of pathology. 1996; 179(1):89–94. Epub 1996/05/01. https://doi.org/10.1002/(SICI)1096-9896(199605)179:1<89::AID-PATH546>3.0.CO;2-R PMID: 8691351.

35. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free radical biology & medicine. 2010; 49(11):1603–16. Epub 2010/09/16. https://doi.org/10.1016/j.freeradbiomed.2010.09.006 PMID: 20840865; PubMed Central PMCID: PMC2990475.

36. Qiu Y, Korteweg C, Chen Z, Li J, Luo J, Huang G, et al. Immunoglobulin G expression and its colocalization with complement proteins in papillary thyroid cancer. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2012; 25(1):36–45. https://doi.org/10.1038/modpathol.2011.139 PMID: 21909078.

37. Ehlers M, Schott M. Hashimoto’s thyroiditis and papillary thyroid cancer: are they immunologically linked? Trends in endocrinology and metabolism: TEM. 2014; 25(12):656–64. Epub 2014/10/14. https://doi.org/10.1016/j.tem.2014.09.001 PMID: 25306886.

38. Zeppa P, Cozzolino I, Peluso AL, Troncone G, Lucariello A, Picardi M, et al. Cytologic, flow cytometry, and molecular assessment of lymphoid infiltrate in fine-needle cytology samples of Hashimoto thyroiditis. Cancer. 2009; 117(3):174–84. https://doi.org/10.1002/cncr.20022 PMID: 19382168.

39. Groot Kormelink T, Pove DG, Kuipers SA, Abudukelimu A, Fens MH, Pieters EH, et al. Immunoglobulin light chain gene expression and its colocalization with complement proteins in papillary thyroid cancer. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2012; 25(1):36–45. https://doi.org/10.1038/modpathol.2011.139 PMID: 21909078.

40. Smith MJ, Rihanek M, Coleman BM, Gottlieb PA, Sarapura VD, Cambier JC. Activation of thyroid antigen-reactive B cells in recent onset autoimmune thyroid disease patients. Journal of autoimmunity. 2018; 89:82–9. Epub 2017/12/14. https://doi.org/10.1016/j.jaut.2017.12.001 PMID: 29233566; PubMed Central PMCID: PMC5902436.

41. Yeh SJ, Lin CY, Li CW, Chen BS. Systems Biology Approaches to Investigate Genetic and Epigenetic Molecular Progression Mechanisms for Identifying Gene Expression Signatures in Papillary Thyroid
44. Morgan AA, Pyrgos VJ, Nadeau KC, Williamson PR, Butte AJ. Multiplex meta-analysis of RNA expression to identify genes with variants associated with immune dysfunction. Journal of the American Medical Informatics Association: JAMIA. 2012; 19(2):284–8. Epub 2012/02/10. https://doi.org/10.1136/amiajn-2011-000657 PMID: 22319178; PubMed Central PMCID: PMC3277634.

45. Kimura HJ, Rocchi R, Landek-Salgado MA, Suzuki K, Chen CY, Kimura M, et al. Influence of signal transducer and activator of transcription-1 signaling on thyroid morphology and function. Endocrinology. 2009; 150(7):3409–16. Epub 2009/03/28. https://doi.org/10.1210/en.2008-1769 PMID: 19325004; PubMed Central PMCID: PMC2703527.

46. Engeland K. Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM. Cell cycle. 2018; 17(11):1472–81. Epub 2018/05/15. https://doi.org/10.1186/s12964-018-0286-6 PMID: 30208972; PubMed Central PMCID: PMC6134688.

47. Morgan AA, Pyrgos VJ, Nadeau KC, Williamson PR, Butte AJ. Multiplex meta-analysis of RNA expression to identify genes with variants associated with immune dysfunction. Journal of the American Medical Informatics Association: JAMIA. 2012; 19(2):284–8. Epub 2012/02/10. https://doi.org/10.1136/amiajn-2011-000657 PMID: 22319178; PubMed Central PMCID: PMC3277634.

48. Hrdinka M, Horejsi V. PAG—a multipurpose transmembrane adaptor protein. Oncogene. 2014; 33(41):4881–92. Epub 2013/11/12. https://doi.org/10.1038/onc.2013.485 PMID: 24213579.

49. Du X, Tang Y, Xu H, Lit L, Walker W, Ashwood P, et al. Genomic profiles for human peripheral blood T cells, B cells, natural killer cells, monocytes, and polymorphonuclear cells: comparisons to ischemic stroke, migraine, and Tourette syndrome. Genomics. 2006; 87(6):693–703. Epub 2006/03/21. https://doi.org/10.1016/j.ygeno.2006.02.003 PMID: 16546348.

50. Soares-Sousa P, de Prati AC, Ciampa AR, Cavalieri E, Zaffini R, Darra E, Menegazzi M, et al. STAT1 as a new molecular target of anti-inflammatory treatment. Current medicinal chemistry. 2005; 12(16):1819–28. Epub 2005/08/17. https://doi.org/10.2174/092986705454645 PMID: 16101503.

51. Soares-Sousa P, de Prati AC, Ciampa AR, Cavalieri E, Zaffini R, Darra E, Menegazzi M, et al. STAT1 as a new molecular target of anti-inflammatory treatment. Current medicinal chemistry. 2005; 12(16):1819–28. Epub 2005/08/17. https://doi.org/10.2174/092986705454645 PMID: 16101503.

52. Lim MB, Kuiper JW, Katchky A, Goldberg H, Glogauer M. Rac2 is required for the formation of neutrophil extracellular traps. Journal of leukocyte biology. 2011; 90(4):771–6. Epub 2011/06/30. https://doi.org/10.1189/jlb.01110549 PMID: 21712395.

53. Joshi S, Singh AR, Zulcic M, Bao L, Messer K, Ideker T, et al. Rac2 controls tumor growth, metastasis and M1-M2 macrophage differentiation in vivo. PloS one. 2014; 9(4):e95893. Epub 2014/04/29. https://doi.org/10.1371/journal.pone.0095893 PMID: 24770345.

54. Abramson J, Giraud M, Benoist C, Mathis D. Aire's partners in the molecular control of immunological tolerance. Cell. 2010; 140(1):123–35. Epub 2010/01/21. https://doi.org/10.1016/j.cell.2009.12.030 PMID: 20085707.

55. Wong YL, Anzola JV, Davis RL, Yoon M, Motamedi A, Kroll A, et al. Cell biology. Reversible centriole depletion with an inhibitor of Polo-like kinase 4. Science (New York, NY). 2015; 349(6244):1246–50. Epub 2015/05/02. https://doi.org/10.1126/science.aaa1511 PMID: 25931445; PubMed Central PMCID: PMC4764081.

56. Liao GB, Li XZ, Zeng S, Liu C, Yang SM, Yang L, et al. Regulation of the master regulator FOXM1 in cancer. Cell communication and signaling: CCS. 2018; 16(1):57. Epub 2018/09/14. https://doi.org/10.1186/s12964-018-0286-6 PMID: 30208972; PubMed Central PMCID: PMC6134688.

57. Engeland K. Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM. Cell death and differentiation. 2018; 25(1):114–32. Epub 2017/11/11. https://doi.org/10.1038/cdd.2017.172 PMID: 29125603; PubMed Central PMCID: PMC5729532.

58. Ahmed M, Uddin S, Hussain AR, Alyan A, Jehan Z, Al-Dayel F, et al. FoxM1 and its association with matrix metalloproteinases (MMP) signaling pathway in papillary thyroid carcinoma. The Journal of Genetics of Hashimoto's thyroiditis and papillary thyroid carcinoma with Hashimoto's thyroiditis.
PARP3 comes to light as a prime target in cancer.

Karicheva O, Rodriguez-Vargas JM, Wadier N, Martin-Hernandez K, Vauchelles R, Magroun N, et al.

Marcello MA, Morari EC, Cunha LL, De Nadai Silva AC, Carraro DM, Carvalho AL, et al. P53 and PARP3 controls TGFbeta and ROS driven epithelial-to-mesenchymal transition and stemness by stimulating a TG2-Snail-E-cadherin axis. Oncotarget. 2016; 7(39):64109–23. Epub 2016/09/01. https://doi.org/10.1038/onc.2016.255 PMID: 27579892; PubMed Central PMCID: PMC5265429.

Rodriguez-Vargas JM, Nguekeu-Zebaze L, Dantzer F. PARP3 comes to light as a prime target in cancer therapy. Cell cycle (Georgetown, Tex). 2019; 18(12):1295–301. Epub 2019/05/17. https://doi.org/10.1080/15384101.2019.1617454 PMID: 31054444; PubMed Central PMCID: PMC6592235.

Marcello MA, Morari EC, Cunha LL, De Nadai Silva AC, Carraro DM, Carvalho AL, et al. P53 and expression of immunological markers may identify early stage thyroid tumors. Clinical & developmental immunology. 2013; 2013:246584. Epub 2013/10/31. https://doi.org/10.1155/2013/846584 PMID: 24171036; PubMed Central PMCID: PMC3792553.

Bai P. Biology of Poly(ADP-Ribose) Polymerases: The Factotum of Cell Maintenance. Molecular cell. 2012-2555 PMID: 23118425.
77. Okayasu I, Osakabe T, Onozawa M, Mikami T, Fujiwara M. p53 and p21(WAF1) expression in lymphocytic thyroiditis and thyroid tumors. Clinical immunology and immunopathology. 1998; 88(2):183–91. Epub 1998/08/26. https://doi.org/10.1006/clin.1998.4572 PMID: 9714696.

78. Cammarota F, Fiscardi F, Esposito T, de Vita G, Salvatore M, Laukkanen MO. Clinical relevance of thyroid cell models in redox research. Cancer cell international. 2015; 15:113. Epub 2015/12/15. https://doi.org/10.1186/s12935-015-0264-3 PMID: 26664298; PubMed Central PMCID: PMC4673788.

79. Rao SSP, Huang SC, Glenn St Hilaire B, Engreitz JM, Perez EM, Kieffer-Kwon KR, et al. Cohesin Loss Eliminates All Loop Domains. Cell. 2017; 171(2):305–20.e24. Epub 2017/10/07. https://doi.org/10.1016/j.cell.2017.09.026 PMID: 28985562; PubMed Central PMCID: PMC5846482.

80. O’Neil NJ, van Pel DM, Hieter P. Synthetic lethality and cancer: cohesin and PARP at the replication fork. Trends in genetics: TIG. 2013; 29(5):290–7. Epub 2013/01/22. https://doi.org/10.1016/j.tig.2012.12.004 PMID: 23333522; PubMed Central PMCID: PMC3886440.

81. Gorodetska I, Kozeretska I, Dubrovskaya A. BRCA Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance. Journal of Cancer. 2019; 10(9):2109–27. Epub 2019/06/18. https://doi.org/10.7150/jca.30410 PMID: 31205572; PubMed Central PMCID: PMC6548160.

82. Yi YW, Kang HJ, Kim HJ, Hwang JS, Wang A, Bae I. Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells. Molecular carcinogenesis. 2013; 52(9):667–75. Epub 2012/04/11. https://doi.org/10.1002/mc.21905 PMID: 22488590; PubMed Central PMCID: PMC3586771.

83. Nersita R, Matrone A, Klain M, Scavuzzo F, Vitolo G, Abbondanza C, et al. Decreased serum vascular endothelial growth factor-D levels in metastatic patients with differentiated thyroid carcinoma. Clinical endocrinology. 2012; 76(1):142–6. Epub 2011/07/26. https://doi.org/10.1111/j.1365-2265.2011.04183.x PMID: 21781145.